RETRACTED: A subset of PARP inhibitors induces lethal telomere fusion in ALT-dependent tumor cells

• Published in: Science translational medicine Vol. 13; no. 592
• Main Authors: Mukherjee, Joydeep, Pandita, Ajay, Kamalakar, Chatla, Johannessen, Tor-Christian, Ohba, Shigeo, Tang, Yongjian, Dalle-Ore, Cecilia L, Bjerkvig, Rolf, Pieper, Russell O
• Format: Journal Article
• Language: English
• Published: United States 05.05.2021
• Subjects: DNA; DNA Damage; Humans; Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors - pharmacology; Telomere - genetics
• ISSN: 1946-6242
• DOI: 10.1126/scitranslmed.abc7211

About 10% of all tumors, including most lower-grade astrocytoma, rely on the alternative lengthening of telomere (ALT) mechanism to resolve telomeric shortening and avoid limitations on their growth. Here, we found that dependence on the ALT mechanism made cells hypersensitive to a subset of poly(ADP-ribose) polymerase inhibitors (PARPi). We found that this hypersensitivity was not associated with PARPi-created genomic DNA damage as in most PARPi-sensitive populations but rather with PARPi-induced telomere fusion. Mechanistically, we determined that PARP1 was recruited to the telomeres of ALT-dependent cells as part of a DNA damage response. By recruiting MRE11 and BRCC3 to stabilize TRF2 at the ends of telomeres, PARP1 blocked chromosomal fusion. Exposure of ALT-dependent tumor cells to a subset of PARPi induced a conformational change in PARP1 that limited binding to MRE11 and BRCC3 and delayed release of the TRF2-mediated block on lethal telomeric fusion. These results therefore provide a basis for PARPi treatment of ALT-dependent tumors, as well as establish chromosome fusion as a biomarker of their activity.